Literature DB >> 16339331

Angiotensin-converting enzyme inhibition intervention in elderly persons: effects on body composition and physical performance.

Christy S Carter1, Graziano Onder, Stephen B Kritchevsky, Marco Pahor.   

Abstract

The disablement process is often accompanied by sarcopenia or muscle loss, which is associated with virtually all identified disability risk factors. Clinically, the association between body composition and physical performance has been documented by several studies. However, loss of strength is greater than loss of muscle mass with age implying that the quality of remaining muscle may be reduced. Although there are limited data explaining potential physiological mechanisms that contribute to muscle quality, sarcopenia is frequently associated with fat accumulation, and the percentage of body fat increases with age even if weight does not. However, the relationship between fat and muscle function may not be linear, suggesting that there may be an optimal ratio of lean to fat mass for physical function. There are no definitive pharmacological interventions proven to prevent decline in physical function either by modulating body composition or by other means. One exception may be angiotensin-converting enzyme inhibitors (ACEIs). ACE is an important component of the renin-angiotensin system, the central hormonal regulator of blood pressure. Recent evidence suggests that ACEIs may improve physical function by means of direct effects on body composition in older persons, rather than through its blood-pressure-lowering effects. Clinical and genetic studies in humans and experimental evidence in animals suggest that modulation of the renin-angiotensin system is associated with metabolic and biochemical changes in skeletal muscle and fat, changes that are associated with declining physical function. ACEIs may modulate this process through a variety of molecular mechanisms including their influence on oxidative stress and on metabolic and inflammation pathways. This review describes potential biological mechanisms of ACE inhibition and its contribution to declining physical performance and changing body composition. Promising pharmacoepidemiological studies and experimental evidence in animals suggest that there are appropriate models in which to study this effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339331     DOI: 10.1093/gerona/60.11.1437

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  32 in total

1.  Toward an integrated research agenda for critical illness in aging.

Authors:  Eric B Milbrandt; Basil Eldadah; Susan Nayfield; Evan Hadley; Derek C Angus
Journal:  Am J Respir Crit Care Med       Date:  2010-06-17       Impact factor: 21.405

2.  Angiotensin-converting enzyme inhibitor use by older adults is associated with greater functional responses to exercise.

Authors:  Thomas W Buford; Todd M Manini; Fang-Chi Hsu; Matteo Cesari; Stephen D Anton; Susan Nayfield; Randall S Stafford; Timothy S Church; Marco Pahor; Christy S Carter
Journal:  J Am Geriatr Soc       Date:  2012-06-21       Impact factor: 5.562

Review 3.  Sarcopenia: diagnosis and treatment.

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

Review 4.  Management of obesity in the elderly: too much and too late?

Authors:  R L Kennedy; U Malabu; M Kazi; V Shahsidhar
Journal:  J Nutr Health Aging       Date:  2008-11       Impact factor: 4.075

Review 5.  The role of the cell-matrix interface in aging and its interaction with the renin-angiotensin system in the aged vasculature.

Authors:  Maria De Luca
Journal:  Mech Ageing Dev       Date:  2018-04-04       Impact factor: 5.432

6.  Is there a new role for angiotensin-converting-enzyme inhibitors in elderly patients?

Authors:  Ann Cranney
Journal:  CMAJ       Date:  2007-10-09       Impact factor: 8.262

Review 7.  Usefulness of preclinical models for assessing the efficacy of late-life interventions for sarcopenia.

Authors:  Christy S Carter; Emanuele Marzetti; Christiaan Leeuwenburgh; Todd Manini; Thomas C Foster; Leanne Groban; Philip J Scarpace; Drake Morgan
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-06-02       Impact factor: 6.053

Review 8.  The renin-angiotensin system and prevention of age-related functional decline: where are we now?

Authors:  Corey B Simon; Brittany Lee-McMullen; Dane Phelan; Janine Gilkes; Christy S Carter; Thomas W Buford
Journal:  Age (Dordr)       Date:  2015-02-09

9.  Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study.

Authors:  T A Ashfield; H E Syddall; H J Martin; E M Dennison; C Cooper; A Aihie Sayer
Journal:  Age Ageing       Date:  2009-12-17       Impact factor: 10.668

10.  Predictors of Change in Physical Function in Older Adults in Response to Long-Term, Structured Physical Activity: The LIFE Study.

Authors:  Andrew S Layne; Fang-Chi Hsu; Steven N Blair; Shyh-Huei Chen; Jennifer Dungan; Roger A Fielding; Nancy W Glynn; Alexandra M Hajduk; Abby C King; Todd M Manini; Anthony P Marsh; Marco Pahor; Christine A Pellegrini; Thomas W Buford
Journal:  Arch Phys Med Rehabil       Date:  2016-08-25       Impact factor: 3.966

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.